9:03 am Seattle Genetics highlights ADCETRIS (Brentuximab Vedotin) clinical data that demonstrate 92% objective response rate in ongoing Phase 1/2 clinical trial evaluating ADCETRIS in combination with Bendamustine
View todays social media effects on SGEN
View the latest stocks trending across Twitter. Click to view dashboard
See who Seattle is hiring next, click here to view
